Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Cytek Biosciences, Inc. (CTKB) had Debt to Equity Ratio of 0.00 for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$53.23M |
|
$-6.10M |
|
$22.02M |
|
$31.21M |
|
$61.65M |
|
$-8.42M |
|
$1.51M |
|
$-6.91M |
|
$-6.91M |
|
$-6.10M |
|
$-6.10M |
|
$-6.10M |
|
$-6.10M |
|
$-8.42M |
|
$-5.31M |
|
130.36M |
|
130.36M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$378.94M |
|
$20.61M |
|
$67.21M |
|
$446.14M |
|
$84.95M |
|
$0.10M |
|
$39.84M |
|
$124.79M |
|
$321.35M |
|
$290.63M |
|
$321.35M |
|
130.77M |
|
| Cash Flow Statement Financials | |
$-5.82M |
|
$-21.86M |
|
$2.61M |
|
$90.85M |
|
$67.19M |
|
$-23.66M |
|
$15.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.46 |
|
-- |
|
-- |
|
0.00 |
|
|
Debt to Equity Ratio |
0.00 |
58.63% |
|
-15.82% |
|
-15.82% |
|
-- |
|
-12.98% |
|
-11.45% |
|
$-11.63M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.42 |
|
0.90 |
|
100.08 |
|
-1.90% |
|
-2.10% |
|
-1.37% |
|
-1.90% |
|
$2.46 |
|
$-0.09 |
|
$-0.04 |
|